Cargando…
Pegaptanib sodium for ocular vascular disease
Pegaptanib sodium (Macugen(TM)) is a selective RNA aptamer that inhibits vascular endothelial growth factor (VEGF)( 165) , the VEGF isoform primarily responsible for pathologic ocular neovascularization and vascular permeability, while sparing the physiological isoform VEGF( 121) . After more than 1...
Autores principales: | Shukla, Dhananjay, Namperumalsamy, Perumalsamy, Goldbaum, Mauro, Cunningham Jr, Emmett T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2635976/ https://www.ncbi.nlm.nih.gov/pubmed/17951898 |
Ejemplares similares
-
A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
por: Nagpal, Manish, et al.
Publicado: (2007) -
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial
por: Singerman, L J, et al.
Publicado: (2008) -
Clinical experience with pegaptanib sodium
por: Rosina, Chiara, et al.
Publicado: (2008) -
The importance of pegaptanib sodium treatment for patients with vascular active vitreoretinopathy
por: Zhang, Rui, et al.
Publicado: (2017) -
Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
por: Querques, G., et al.
Publicado: (2009)